4.6 Article

A Fluorescent Carbon Nanotube Sensor Detects the Metastatic Prostate Cancer Biomarker uPA

Journal

ACS SENSORS
Volume 3, Issue 9, Pages 1838-1845

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acssensors.8b00631

Keywords

biosensor; optical sensor; protein; nanocarbon; nanomedicine; prostatic carcinoma

Funding

  1. NIH New Innovator Award [DP2-HD075698]
  2. NIH Cancer Center Support Grant [P30 CA008748]
  3. National Science Foundation CAREER Award [1752506]
  4. Honorable Tina Brozman Foundation for Ovarian Cancer Research
  5. American Cancer Society
  6. Pershing Square Sohn Cancer Research Alliance
  7. Expect Miracles Foundation - Financial Services Against Cancer
  8. Louis V. Gerstner Jr. Young Investigator's Fund
  9. Frank A. Howard Scholars Program
  10. Alan and Sandra Gerry Metastasis Research Initiative
  11. Center for Molecular Imaging and Nanotechnology at Memorial Sloan Kettering Cancer Center
  12. Cycle for Survival
  13. Anna Fuller Fund
  14. Commonwealth Foundation for Cancer Research
  15. Imaging and Radiation Sciences Program
  16. Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center
  17. Ovarian Cancer Research Fund [370463]
  18. American Heart Association [17POST33650043]
  19. NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Therapeutic outcomes in patients with prostate cancer are hindered by the inability to discern indolent versus aggressive disease. To address this problem, we developed a quantitative fluorescent nanosensor for the cancer biomarker urokinase plasminogen activator (uPA). We used the unique fluorescent characteristics of single-walled carbon nanotubes (SWCNT) to engineer an optical sensor that responds to uPA via optical bandgap modulation in complex protein environments. The sensing characteristics of this construct were modulated by passivation of the hydrophobic SWCNT surface with bovine serum albumin (BSA). The sensor enabled quantitative detection of known uPA concentrations in human blood products. These experiments potentiate future use of this technology as a rapid, point-of-care sensor for biomarker measurements in patient fluid samples. We expect that further work will develop a method to discern aggressive vs indolent prostate cancer and reduce overtreatment of this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available